Alfred Böcking
Alfred Böcking has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
Josef Dietz
Bundesverband Prostatakrebs Selbsthilfe, BPS, Bretten, Germany
2 shared publicationsStefan Biesterfeld
Institute of Pathology, Koblenz, Germany
2 shared publicationsA. Fabarius
Medizinische Fakultät Mannheim, Universität Heidelberg, Heidelberg, Germany
1 shared publicationA. Voskanyan
Medizinische Fakultät Mannheim, Universität Heidelberg, Heidelberg, Germany
1 shared publicationAaron S. Taudt
European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, A. Deusinglaan 1, NL-9713 AV, Groningen, The Netherlands
1 shared publication- Aleksei Anatolyevich Stepanenko
Department of Fundamental and Applied Neurobiology, V.P. Serbsky Federal Medical Research Center for Psychiatry and Narcology, Moscow 119034, Russia
1 shared publication
Latest Publications
- 14 June 2024
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 121 (12) , 413
Correspondence
- 14 June 2024
- Published by Deutscher Arzte-Verlag GmbH in Deutsches Ärzteblatt international
- Vol. 121 (12) , 413
Correspondence
- Open Access
DNA Karyometry for Automated Detection of Cancer Cells
Background: Microscopical screening of cytological samples for the presence of cancer cells at high throughput with sufficient diagnostic accuracy requires highly specialized personnel which is not available in most countries. Methods: Using commercially available automated microscope-based screeners (MotiCyte and EasyScan), software was developed which is able to classify Feulgen-stained nuclei into eight diagnostically relevant types, using supervised machine learning. the nuclei belonging to normal cells were used for internal calibration of the nuclear DNA content while nuclei belonging to those suspicious of being malignant were specifically identified. The percentage of morphologically abnormal nuclei was used to identify samples suspected of malignancy, and the proof of DNA-aneuploidy was used to definitely determine the state malignancy. A blinded study was performed using oral smears from 92 patients with Fanconi anemia, revealing oral leukoplakias or erythroplakias. In an earlier study, we compared diagnostic accuracies on 121 serous effusion specimens. In addition, using a blinded study employing 80 patients with prostate cancer who were under active surveillance, we aimed to identify those whose cancers would not advance within 4 years. Results: Applying a threshold of the presence of >4% of morphologically abnormal nuclei from oral squamous cells and DNA single-cell or stemline aneuploidy to identify samples suspected of malignancy, an overall diagnostic accuracy of 91.3% was found as compared with 75.0% accuracy determined by conventional subjective cytological assessment using the same slides. Accuracy of automated screening effusions was 84.3% as compared to 95.9% of conventional cytology. No prostate cancer patients under active surveillance, revealing DNA-grade 1, showed progress of their disease within 4.1 years. Conclusions: An automated microscope-based screener was developed which is able to identify malignant cells in different types of human specimens with a diagnostic accuracy comparable with subjective cytological assessment. Early prostate cancers which do not progress despite applying any therapy could be identified using this automated approach.
Open AccessDNA Karyometry for Automated Detection of Cancer Cells
Background: Microscopical screening of cytological samples for the presence of cancer cells at high throughput with sufficient diagnostic accuracy requires highly specialized personnel which is not available in most countries. Methods: Using commercially available automated microscope-based screeners (MotiCyte and EasyScan), software was developed which is able to classify Feulgen-stained nuclei into eight diagnostically relevant types, using supervised machine learning. the nuclei belonging to normal cells were used for internal calibration of the nuclear DNA content while nuclei belonging to those suspicious of being malignant were specifically identified. The percentage of morphologically abnormal nuclei was used to identify samples suspected of malignancy, and the proof of DNA-aneuploidy was used to definitely determine the state malignancy. A blinded study was performed using oral smears from 92 patients with Fanconi anemia, revealing oral leukoplakias or erythroplakias. In an earlier study, we compared diagnostic accuracies on 121 serous effusion specimens. In addition, using a blinded study employing 80 patients with prostate cancer who were under active surveillance, we aimed to identify those whose cancers would not advance within 4 years. Results: Applying a threshold of the presence of >4% of morphologically abnormal nuclei from oral squamous cells and DNA single-cell or stemline aneuploidy to identify samples suspected of malignancy, an overall diagnostic accuracy of 91.3% was found as compared with 75.0% accuracy determined by conventional subjective cytological assessment using the same slides. Accuracy of automated screening effusions was 84.3% as compared to 95.9% of conventional cytology. No prostate cancer patients under active surveillance, revealing DNA-grade 1, showed progress of their disease within 4.1 years. Conclusions: An automated microscope-based screener was developed which is able to identify malignant cells in different types of human specimens with a diagnostic accuracy comparable with subjective cytological assessment. Early prostate cancers which do not progress despite applying any therapy could be identified using this automated approach.
- Open Access
- 19 October 2018
- Published by Wiley in Cancer Cytopathology
- Vol. 127 (1) , 18-25
Automated detection of cancer cells in effusion specimens by DNA karyometry
BACKGROUND The average sensitivity of conventional cytology for the identification of cancer cells in effusion specimens is only approximately 58%. DNA image cytometry (DNA‐ICM), which exploits the DNA content of morphologically suspicious nuclei measured on digital images, has a sensitivity of up to 91% for the detection of cancer cells. However, when performed manually, to our knowledge to date, an expert needs approximately 60 minutes for the analysis of a single slide. METHODS In the current study, the authors present a novel method of supervised machine learning for the automated identification of morphologically suspicious mesothelial and epithelial nuclei in Feulgen‐stained effusion specimens. The authors compared this with manual DNA‐ICM and a gold standard cytological diagnosis for 121 cases. Furthermore, the authors retrospectively analyzed whether the amount of morphometrically abnormal mesothelial or epithelial nuclei detected by the digital classifier could be used as an additional diagnostic marker. RESULTS The presented semiautomated DNA karyometric solution identified more diagnostically relevant abnormal nuclei compared with manual DNA‐ICM, which led to a higher sensitivity (76.4% vs 68.5%) at a specificity of 100%. The ratio between digitally abnormal and all mesothelial nuclei was found to identify cancer cell–positive slides at 100% sensitivity and 70% specificity. The time effort for an expert therefore is reduced to the verification of a few nuclei with exceeding DNA content, which to our knowledge can be accomplished within 5 minutes. CONCLUSIONS The authors have created and validated a computer‐assisted bimodal karyometric approach for which both nuclear morphology and DNA are quantified from a Feulgen‐stained slide. DNA karyometry thus increases the diagnostic accuracy and reduces the workload of an expert when compared with manual DNA‐ICM.
- 19 October 2018
- Published by Wiley in Cancer Cytopathology
- Vol. 127 (1) , 18-25
Open AccessAutomated detection of cancer cells in effusion specimens by DNA karyometry
BACKGROUND The average sensitivity of conventional cytology for the identification of cancer cells in effusion specimens is only approximately 58%. DNA image cytometry (DNA‐ICM), which exploits the DNA content of morphologically suspicious nuclei measured on digital images, has a sensitivity of up to 91% for the detection of cancer cells. However, when performed manually, to our knowledge to date, an expert needs approximately 60 minutes for the analysis of a single slide. METHODS In the current study, the authors present a novel method of supervised machine learning for the automated identification of morphologically suspicious mesothelial and epithelial nuclei in Feulgen‐stained effusion specimens. The authors compared this with manual DNA‐ICM and a gold standard cytological diagnosis for 121 cases. Furthermore, the authors retrospectively analyzed whether the amount of morphometrically abnormal mesothelial or epithelial nuclei detected by the digital classifier could be used as an additional diagnostic marker. RESULTS The presented semiautomated DNA karyometric solution identified more diagnostically relevant abnormal nuclei compared with manual DNA‐ICM, which led to a higher sensitivity (76.4% vs 68.5%) at a specificity of 100%. The ratio between digitally abnormal and all mesothelial nuclei was found to identify cancer cell–positive slides at 100% sensitivity and 70% specificity. The time effort for an expert therefore is reduced to the verification of a few nuclei with exceeding DNA content, which to our knowledge can be accomplished within 5 minutes. CONCLUSIONS The authors have created and validated a computer‐assisted bimodal karyometric approach for which both nuclear morphology and DNA are quantified from a Feulgen‐stained slide. DNA karyometry thus increases the diagnostic accuracy and reduces the workload of an expert when compared with manual DNA‐ICM.
- Open Access
- 19 June 2017
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 10 (S2) , 77-94
Abstracts from the 3rd Conference on Aneuploidy and Cancer: Clinical and Experimental Aspects
- 19 June 2017
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 10 (S2) , 77-94
Open AccessAbstracts from the 3rd Conference on Aneuploidy and Cancer: Clinical and Experimental Aspects
- 26 August 2015
- Published by Springer Nature in Der Pathologe
- Vol. 36 (5) , 498-502
Objective DNA malignancy grading as adjunct to the histological Gleason score
- 26 August 2015
- Published by Springer Nature in Der Pathologe
- Vol. 36 (5) , 498-502
Objective DNA malignancy grading as adjunct to the histological Gleason score
- Open Access
- 18 April 2015
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 8 (1) , 1-3
Comparability of tumor-cytogenetics and -DNA-cytometry
Knowledge of the karyotypes of cancer cells is the theoretical underpinning of diagnostic/prognostic DNA-cytometry. Currently the translation is hampered by different terminologies of both fields. The following letter tries to close current gaps between the two fields by harmonizing their different terminologies.
- 18 April 2015
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 8 (1) , 1-3
Open AccessComparability of tumor-cytogenetics and -DNA-cytometry
Knowledge of the karyotypes of cancer cells is the theoretical underpinning of diagnostic/prognostic DNA-cytometry. Currently the translation is hampered by different terminologies of both fields. The following letter tries to close current gaps between the two fields by harmonizing their different terminologies.
- Open Access
- 1 January 2014
- Published by Herbert Publications PVT LTD in Pathology Discovery
- Vol. 2 (1) , 7
DNA-cytometric grading of prostate cancer Systematic review with descriptive data analysis
Gleason-score <=6, assessed on core needle biopsies, is an essential prognostic parameter to offer the strategy of Active Surveillance (AS) to patients with locally confined cancers of the prostate. Yet, its interobserver
- 1 January 2014
- Published by Herbert Publications PVT LTD in Pathology Discovery
- Vol. 2 (1) , 7
Open AccessDNA-cytometric grading of prostate cancer Systematic review with descriptive data analysis
Gleason-score <=6, assessed on core needle biopsies, is an essential prognostic parameter to offer the strategy of Active Surveillance (AS) to patients with locally confined cancers of the prostate. Yet, its interobserver